Teva Pharmaceutical’s new investigational treatment for MS
21 March 2013 | By PARADIGM COMMUNICATIONS
TEVA and Active Biotech announced top-line results from the open-label extension of the Phase III ALLEGRO study...
List view / Grid view
News
Effect of Genzyme’s LEMTRADA maintained in patients beyond two-year pivotal MS studies
21 March 2013 | By Sanofi
Results from the first year of the extension study of LEMTRADA™ (alemtuzumab)...
Sanofi launches 2013 Patient Group Bursary Scheme
21 March 2013 | By Just:: Health PR
2013 Patient Group Bursary Scheme launched...
AstraZeneca appoints Marc Dunoyer as Executive Vice President, Global Portfolio & Product Strategy
21 March 2013 | By AstraZeneca
AstraZeneca announced that Marc Dunoyer is to join the company...
Takeda launches new subsidiary in Ecuador
21 March 2013 | By Takeda Pharmaceuticals International GmbH (Takeda)
Takeda announced further expansion of its presence in Latin America with the launch of its wholly-owned subsidiary in Ecuador...
AstraZeneca and Karolinska Institutet to create Integrated Translational Research Centre
21 March 2013 | By AstraZeneca
The Centre will be set up to conduct preclinical and clinical studies...
AstraZeneca and Moderna Therapeutics announce exclusive agreement
21 March 2013 | By AstraZeneca
Agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer...
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
21 March 2013 | By Novartis
New data presented...
AstraZeneca outlines strategy to return to growth and achieve scientific leadership
21 March 2013 | By AstraZeneca
AstraZeneca will outline its strategy to return to growth and achieve scientific leadership...
3rd Annual Dissolution Symposium on June 3-4 2013
20 March 2013 | By Sirius Analytical Instruments Ltd
The University of Bath, Department of Pharmacy and Sirius Analytical invite you to attend the 3rd Annual Dissolution Symposium...
New data show Azilect® provided clinical benefit in patients with early Parkinson’s
20 March 2013 | By H. Lundbeck A/S
Results add to evidence for Azilect as an effective and well-tolerated treatment option at different stages of the progression of PD...
Positive year one results from Biogen Idec Phase 3 ADVANCE trial of PLEGRIDY™ presented at AAN Meeting
20 March 2013 | By Biogen Idec
“These full first-year results provide a more complete picture of PLEGRIDY..."
FDA Advisory Committee votes favorably on Abbott’s minimally invasive MitraClip® device for patients with significant mitral regurgitation who are too high risk for surgery
20 March 2013 | By Abbott
"We appreciate the FDA's dedication of time and resources..."
Boehringer Ingelheim and Lilly initiate MARLINA™ clinical trial to evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and albuminuria
19 March 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company announced today the initiation of a Phase IIIb trial to evaluate the glycaemic efficacy and safety of linagliptin in type 2 diabetes patients with prevalent albuminuria, and urinary albumin-to-creatinine (UACR) ratio 30-3000 mg/g creatinine, in addition to current standard therapy for diabetic nephropathy.…
Real world study comparing commonly prescribed COPD medicines shows choice of treatment has impact on patient outcomes
19 March 2013 | By AstraZeneca
PATHOS a real-world retrospective study...
